JP2020507328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507328A5 JP2020507328A5 JP2019543761A JP2019543761A JP2020507328A5 JP 2020507328 A5 JP2020507328 A5 JP 2020507328A5 JP 2019543761 A JP2019543761 A JP 2019543761A JP 2019543761 A JP2019543761 A JP 2019543761A JP 2020507328 A5 JP2020507328 A5 JP 2020507328A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022196214A JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457780P | 2017-02-10 | 2017-02-10 | |
| US62/457,780 | 2017-02-10 | ||
| PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196214A Division JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507328A JP2020507328A (ja) | 2020-03-12 |
| JP2020507328A5 true JP2020507328A5 (enExample) | 2022-12-26 |
| JP7257323B2 JP7257323B2 (ja) | 2023-04-13 |
Family
ID=63107848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543761A Active JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190375838A1 (enExample) |
| EP (1) | EP3579876A4 (enExample) |
| JP (2) | JP7257323B2 (enExample) |
| KR (2) | KR20240078657A (enExample) |
| CN (1) | CN110461361A (enExample) |
| AU (1) | AU2018219348A1 (enExample) |
| BR (1) | BR112019016424A2 (enExample) |
| CA (1) | CA3054642A1 (enExample) |
| IL (1) | IL268567A (enExample) |
| MA (1) | MA47465A (enExample) |
| MX (1) | MX2019009566A (enExample) |
| MY (1) | MY205850A (enExample) |
| SG (1) | SG11201907253VA (enExample) |
| WO (1) | WO2018148566A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| MX2020002036A (es) * | 2017-08-23 | 2020-03-24 | Dragonfly Therapeutics Inc | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EP3833392A4 (en) * | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3138058A1 (en) * | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| AU2021284401A1 (en) | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
| CN116063550A (zh) * | 2020-09-02 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| CN116368154A (zh) * | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| EP4301402A1 (en) | 2021-03-03 | 2024-01-10 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
| KR20230163485A (ko) * | 2021-03-31 | 2023-11-30 | 얀센 바이오테크 인코포레이티드 | 면역 이펙터 세포 재유도를 위한 물질 및 방법 |
| WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP3663318A1 (en) * | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
| AU2012235758B2 (en) * | 2011-03-25 | 2015-05-07 | IGI Therapeutics SA | Hetero-dimeric immunoglobulins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| SG10202006507XA (en) * | 2012-05-30 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Target-tissue-specific antigen-binding molecule |
| EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US9963513B2 (en) * | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| WO2014179363A1 (en) * | 2013-04-29 | 2014-11-06 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| EP3258967A4 (en) * | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| WO2016164308A1 (en) * | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| DK3579848T3 (da) * | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
-
2018
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 BR BR112019016424-3A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en not_active Ceased
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/en active Pending
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending